Apellis Pharmaceuticals (APLS) opened Q1 2026 with total revenue of US$268.3 million and basic EPS of US$0.15, anchored by net income of US$18.7 million, while its trailing 12 month revenue stood at US$1.1 billion with basic EPS of US$1.05 and net income of US$133.3 million. Over recent quarters the company has seen quarterly revenue range from US$166.8 million to US$458.6 million and basic EPS swing between a loss of US$0.74 and a gain of US$1.71, which places this latest quarter within a broader sequence of improving earnings and tighter net profit margins.

See our full analysis for Apellis Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile compares with the widely followed narratives around growth, profitability and risk for Apellis Pharmaceuticals.

Profitability Holds After Volatile Year

• On a trailing 12 month basis, Apellis reports US$1.1b in revenue and US$133.3 million in net income, compared with quarterly revenue over the past year that moved between US$166.8 million and US$458.6 million and net income that ranged from a loss of US$92.2 million to a profit of US$215.7 million.
• What stands out for the bullish view is that this profitability comes after a period of losses and swings in EPS between a loss of US$0.74 and a gain of US$1.71. This heavily supports the argument that recent cost control and product traction are starting to show through, even if earnings have not been consistently high each quarter yet.
  • Bulls point to higher earnings quality and improved net profit margin over the last 12 months. The move from a trailing 12 month loss of US$223.7 million a year ago to a profit of US$133.3 million aligns with that claim.
  • They also highlight that the company is now described as having high quality past earnings, which fits with the shift from negative trailing 12 month EPS of US$1.80 a year ago to positive trailing 12 month EPS of US$1.05 today.

Bulls argue that this shift to profitability is just the beginning and that key products can support much higher earnings over time. If you want to see how that story is laid out in full, check the 🐂 Apellis Pharmaceuticals Bull Case

Revenue Growth Trails Market Benchmarks

• Trailing 12 month revenue growth is reported at 10.3% per year, which sits slightly below the 11.3% per year benchmark given for the wider US market, even though Apellis has moved from trailing 12 month revenue of US$781.4 million a year ago to US$1.1b now.
• Critics in the bearish camp focus on this gap, arguing that a business growing revenue a touch slower than the broader market but carrying high research costs faces pressure to maintain its new profitability. They question how durable earnings will be if revenue growth remains around 10.3% per year while competition in key indications intensifies.
  • Bears also highlight that sales are concentrated in a small product set, so any slowdown from these products could have an outsized effect, especially when much of the reported topline has to offset ongoing research and commercial spend.
  • They tie this to the risk that heavier use of free goods and patient assistance programs can weigh on reported revenue, which would matter more if revenue growth stays below the market benchmark for an extended period.

Skeptics warn that slower revenue growth and product concentration could matter more than today's profitability. If you want to see their full case, have a look at the 🐻 Apellis Pharmaceuticals Bear Case

Valuation Signals And Volatility Tension

• At a current share price of US$41.01, the stock trades on a P/S of 5.2x, which sits below the 10.8x average for US biotechs and the 14.4x peer average. The provided DCF fair value of US$111.61 and the analyst consensus price target of US$40.93 together suggest pricing that is close to consensus expectations but materially below the DCF figure.
• Consensus narrative points out that this mix of lower P/S multiples and a much higher DCF fair value can look appealing. At the same time, the same data set flags elevated share price volatility over the past three months, so investors weighing the story have to balance the relative value signals against the reality that the stock has been moving around more sharply than the broader US market.
  • On the supportive side, trailing 12 month earnings are positive and the company is now described as having improved net margins, which helps explain why some models arrive at a DCF fair value well above the current share price.
  • On the cautionary side, the combination of high volatility and revenue growth that sits below the market benchmark means that any setback to the profitability story could have a faster impact on the share price than on a more stable stock.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Apellis Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both the bullish and bearish angles side by side, how do you interpret the balance of risk and reward? How quickly do you want to form your own view based on the underlying data and context? You can ground that view by checking the 4 key rewards and 1 important warning sign

See What Else Is Out There

Apellis shows slower 10.3% annual revenue growth than the broader US market benchmark and relies heavily on a concentrated product set to support profitability.

If that mix of modest growth and concentration risk feels tight for your comfort, compare it with companies in the 74 resilient stocks with low risk scores to see businesses with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.